Background. World Health Organization guidelines for antiretroviral treatment (ART) in resource-limited settings recommend either stavudine or tenofovir as part of initial therapy. We evaluated the clinical outcomes and cost-effectiveness of first-line ART using tenofovir in India, compared with current practice using stavudine or zidovudine.
In the United States and Europe, initial antiretroviral therapy (ART) includes tenofovir, a nucleotide analogue that is more effective and less toxic than stavudine [1] . Current World Health Organization (WHO) guidelines for ART in resource-limited settings recommend either stavudine or tenofovir as part of initial therapy [2] . In much of Asia and other resource-limited settings, the most common first-line regimens for human immunodeficiency virus (HIV)-infected patients contain either stavudine or zidovudine, which are less costly than tenofovir [2, 3] . Although effective, stavudine is associated with toxicities including lipodystrophy, neuropathy, pancreatitis, and the rarer but potentially fatal lactic acidosis; anemia is a common toxicity from zidovudine [4] . In comparison, tenofovir is well tolerated, although it may be associated with nephrotoxicity [5] . Tenofovir is more effective than other nucleoside reverse-transcriptase inhibitor (NRTI) agents [6] . Recent price negotiations and the introduction of generic medications have reduced the cost of tenofovir in many developing countries. Although one African nation (Zambia) has incorporated tenofovir for first-line ART, access remains limited in most of the developing world [7, 8] . NOTE. ART, antiretroviral therapy; d4T, stavudine; HIV, human immunodeficiency virus; PI, protease inhibitor; SD, standard deviation; TDF, tenofovir; ZDV, zidovudine.
a Costs were rounded to the nearest dollar. b Projected using published 24-week data [10, 19] . c Estimated from published 24-and 48-week data [6] . d ART costs were converted from US$ at 2008 value to US$ at 2005 value using the appropriate exchange rates and gross domestic product (GDP) deflators. Additional details and references are available on request.
The National AIDS Control Organization of India reported a plan for scaling up HIV prevention and treatment, aimed at comprehensive HIV care for those infected by 2011 [9] . Our objective was to project the clinical outcomes, cost, and costeffectiveness of various first-line ART regimens in India.
METHODS

Overview and Treatment Strategies
We adapted a published model of HIV treatment in international settings, including southern India [10] . We simulated 4 strategies for the NRTI component for different first-line ART regimens, along with lamivudine and nevirapine, compared with cotrimoxazole prophylaxis alone: (1) a stavudine-containing regimen with zidovudine substituted for stavudine for specified grade 3 or 4 toxicities (neuropathy and pancreatitis) or tenofovir substituted for stavudine in case of lipodystrophy or severe lactic acidosis ("initial stavudine") [11] , (2) a stavudine strategy with zidovudine substituted after 6 months to minimize the risk of lipodystrophy and lactic acidosis ("initial stavudine-to-zidovudine") [12] , (3) a zidovudine strategy with stavudine substituted if anemia developed and a switch to tenofovir if pancreatitis developed ("initial zidovudine") [4, 11] , [6, 19, 23] . To be conservative, we included a probability of anemia from TDF, because anemia was reported, although rarely, in the tenofovir arm [6] . b Rounded to the nearest integer. c We included pancreatitis as an adverse event associated with zidovudine because of a small number of observed cases of this adverse event in the YRG CARE cohort [4] . d We assumed a 1% probability of death from nephrotoxicity resulting from TDF. and (4) a tenofovir-containing regimen in which zidovudine was substituted if nephrotoxicity developed ("initial tenofovir"). All patients had access to 2 sequential "lines" of ART, reflecting Indian guidelines [11] . Second-line ART included tenofovir or zidovudine and a protease inhibitor. We report the incremental cost-effectiveness ratio: the increase in cost divided by the increase in years of life saved (YLS), or quality-adjusted life years saved, compared with the next-lower-cost alternative (US$ at 2005 value/YLS) [13, 14] . We used the modified societal perspective, excluding costs of patients' time and travel; costs and life years were discounted at 3% per year [13] .
Model
By use of first-order Monte Carlo simulation, the model tracks patients selected randomly from an initial distribution of age, sex, CD4 cell count, HIV RNA level, and history of opportunistic infection. Cohort characteristics and clinical events, including CD4 cell counts, HIV RNA level, opportunistic infec- NOTE. Projected life expectancy and quality-adjusted life expectancy were rounded to the nearest one-tenth of a month. Cost and cost-effectiveness results were rounded to the nearest $10. No. of deaths was rounded to the nearest 10 deaths per 100,000 patients. d4T, stavudine; OI, opportunistic infection; TDF, tenofovir; YLS, year of life saved; ZDV, zidovudine.
a Unless otherwise noted, the incremental cost-effectiveness ratios are reported as US$ at 2005 value per YLS, compared with cotrimoxazole alone (no ART). b Weakly dominated: higher cost-effectiveness ratios (and thus less efficient) than the next costlier strategy. c Strongly dominated: higher cost but lower life expectancy than the next less costly strategy.
tions, drug toxicities, and response to ART, determine the transition probabilities between acute and chronic health states until death [15] . Details on patient characteristics from the cohort at the Y. R. Gaitonde Centre for AIDS Research and Education (YRG CARE) in Chennai, India; disease states of the model; derivation of transition probabilities between disease states; and use of cohort data to inform simulations have been published elsewhere [10, [15] [16] [17] . Successful ART decreases HIV RNA levels and, for those virologically suppressed, increases CD4 cell counts, which then decreases the probability of opportunistic infections and mortality. The WHO Commission on Macroeconomics and Health has suggested that cost-effectiveness ratios !3 times the per capita gross domestic product (GDP) (US$1860 in India) might be considered "cost-effective," and ratios below the GDP ($620 in India) might be "very cost-effective" [18] . We used 3 times GDP as a comparative benchmark. The study was approved by the Ethics Board at YRG CARE and the Partners HealthCare Human Subjects Committee (Boston, MA).
Model Input Data
Cohort characteristics. Simulated patients had demographic and disease characteristics based on an HIV-infected cohort of ∼7000 patients from YRG CARE, the largest nongovernmental HIV care center in India (1996 and 2004; Tables 1, 2 , and 3) [10, 16] . Mean age was 33 years; baseline mean CD4 cell count was 318 cells/mL (standard deviation [SD] , 291 cells/mL); 66% of the subjects were male.
ART effectiveness and toxicity. In the absence of clinical trial data from India, the effectiveness of alternative ART regimens was from a published observational cohort in India and from clinical trials in the United States (Table 1) . For first-line regimens including either stavudine or zidovudine, we used 24-week virologic suppression of 73% (!400 copies/mL) and, for those suppressed, a CD4 cell count increase of 132 cells/mL at 24 weeks; once suppressed, probability of virologic failure after 48 weeks ("long-term" failure probability) was estimated at 5%/ month [10, 19] . For first-line tenofovir, we used 85% suppression at 24 weeks [6] . To maintain conservative assumptions with respect to tenofovir, we applied the same immunologic benefit for tenofovir as to other NRTI regimens (132 cells/mL) [6, 19] . Tenofovir had an estimated long-term virologic failure probability of 1%/month [6] . Data on the probabilities of ART toxicity for drug combinations were from YRG CARE or, when lacking, the best alternative sources [4, 23, 24] . We incorporated mortality for severe lactic acidosis (from stavudine) and nephrotoxicity (from tenofovir) as model inputs to estimate life expectancy with different ART regimens. We incorporated local strategies for managing reported toxicities, including singledrug substitutions of another NRTI for patients who developed grade 3 or 4 toxicity (or after 6 months for stavudine) ( Table  2 ) [12] . Those who experienced virologic failure switched to an appropriate second-line regimen [11, 20, 21] .
Costs. ART costs were derived from the Clinton Foundation HIV/AIDS Initiative price list [3] . CD4-specific inpatient and outpatient utilization associated with routine HIV care, acute events, and death were derived from YRG CARE data [16, 22] .
Sensitivity Analyses
We conducted sensitivity analyses including costs of first-and second-line ART, access to 1 or 3 lines of ART, tenofovir effectiveness, second-line ART stopping criteria, probability of and time to severe lactic acidosis and other ART toxicities, and initial CD4 cell count. Because of limited data on nephrotoxicity from tenofovir in resource-limited settings, we conducted 2-way sensitivity analyses varying the incidence of nephrotoxicity in first-and second-line ART. We also performed 2-and 3-way sensitivity analysis on tenofovir cost, effectiveness, and nephrotoxicity; ART availability; and initial CD4 cell count. We assigned utilities reflecting quality of life to all health states and ART toxicities to project quality-adjusted life expectancy. Utility c This incremental cost-effectiveness ratio is reported compared with initial stavudine. d For individuals whose treatment failed a second-line regimen containing zidovudine, third-line ART was assumed to include TDF, emtricitabine, and a protease inhibitor. For those whose previous regimen contained TDF, third-line ART was assumed to contain zidovudine, lamivudine, and a protease inhibitor. Probability of virologic suppression was assumed to be 40% at 24 weeks; 48-week CD4 cell count increase was 121 cells/mL. Monthly cost was assumed to be $80 for all third-line ART regimens. e Long-term virologic effectiveness was calculated using the probabilities of virologic suppression at 24 and 48 weeks. f Life expectancy is adjusted for QOL and reported as discounted quality-adjusted life months saved. g This incremental cost-effectiveness ratio is reported compared with initial stavudine-to-zidovudine. h This was the cost range of the entire initial TDF regimen. We calculated its TDF component and varied the cost of TDF-containing second-line ART accordingly.
weights ranging from 0.0 (death) to 1.0 (perfect health) were derived from studies in the United States or clinical judgment [25] .
RESULTS
Primary Analysis
In a cohort with a mean CD4 cell count of 318 cells/mL, cotrimoxazole treatment alone (no ART) led to a projected mean discounted life expectancy of 36.9 months (40.2 months undiscounted) with discounted lifetime cost of $610 (Table 4) . Initial stavudine led to a discounted life expectancy of 115.5 months (145.3 months) at a cost of $5580. Initial stavudineto-zidovudine resulted in a mean discounted life expectancy of 115.7 months (145.6 months) at a cost of $5710. Initial zidovudine led to a discounted life expectancy of 115.8 life months (145.6 months) at a cost of $5720. Initial tenofovir increased life expectancy to 125.8 months (162.0 months) with a total cost of $5580 (Table 4) . Initial stavudine was associated with 290 deaths from ART toxicity per 100,000 people, compared with 140 deaths/100,000 people when used with a 6-month zidovudine substitution, 70 deaths/100,000 people from initial zidovudine, and 10 deaths/ 100,000 people from initial tenofovir ( Table 4 , far right column).
Initial stavudine had a higher cost-effectiveness ratio than the next most costly strategy and was thus an economically inefficient use of resources ("weakly dominated") [26] . Initial stavudine-to-zidovudine and initial zidovudine resulted in lower life expectancy and higher cost than initial tenofovir and also represented inefficient resource use. Initial tenofovir had an incremental cost-effectiveness ratio of $670/YLS, compared with cotrimoxazole alone.
Sensitivity Analyses
Access to and cost of additional lines of ART. With access to 3 lines of ART, discounted life expectancy for initial tenofovir increased to 132.0 months, and the incremental cost-effectiveness of initial tenofovir increased to $830/YLS, compared with no ART. Decreasing the cost of the lopinavir/ritonavir component of second-line ART by 25%-75% reduced lifetime cost for all first-line alternatives. When these costs were decreased by 75%, initial tenofovir became even more cost-effective: $390/ YLS, compared with no ART.
Effectiveness of tenofovir.
We assumed that all first-line regimens had equal 24-week effectiveness but varied the probability of long-term virologic failure for tenofovir, compared with initial stavudine or zidovudine (Table 5 ) [19] . When we reduced this advantage by 25%-100%, tenofovir remained the only economically efficient strategy, with incremental cost-effectiveness ratios of $700 to $740/YLS, compared with no ART. Thus, even when the effectiveness of all 3 NRTI alternatives was equivalent, as reported in some clinical trial data [27] , the policy-relevant cost-effectiveness results are robust.
Increasing the CD4 gain associated with virologic suppression on initial tenofovir to 190 cells/mL at 48 weeks resulted in a life expectancy gain of 12.8 months [6] , a lifetime cost of $5320, and a cost-effectiveness ratio of $620/YLS, compared with no ART (the tenofovir strategy dominated all other strategies).
Incidence of and mortality from nephrotoxicity. When the frequency of nephrotoxicity was 1.6% in either first-or secondline regimens containing tenofovir, even a mortality rate from nephrotoxicity as high as 90% had little impact on mean total life expectancy (Figure 1 ) or cost-effectiveness (Table 5) .
Initial CD4 cell count. Varying mean initial CD4 cell count from 50 to 500 cells/mL had little effect on the cost-effectiveness results ($670 to $700/YLS).
Quality of life. When adjusted for quality of life, initial tenofovir resulted in a discounted life expectancy of 86.3 quality-adjusted life months (110.3 quality-adjusted life months undiscounted) and a cost-effectiveness ratio of $1000/qualityadjusted life year, compared with no ART. All other strategies were economically inefficient. Similar adjustments in which patients had access to only one line of ART yielded similar results ( Table 5) .
Cost of tenofovir. We varied the cost of tenofovir-containing first-line ART from to $7 to $100/month, with commensurate changes in the tenofovir component of second-line ART (Figure 2 ). When 2 lines of ART were available, initial tenofovir had an incremental cost-effectiveness ratio !3 times per capita GDP in India. If only one line was available, then the costeffectiveness results were more sensitive to changes in tenofovir cost, but initial tenofovir remained cost-effective throughout a plausible range of costs.
Additional sensitivity analyses. Alternative ART stopping criteria for patients in whom second-line ART failed (stop immediately upon virologic failure or severe opportunistic infection) did not substantially affect the cost-effectiveness results (Table 5 ). Other parameters with limited impact included the probability of lactic acidosis from stavudine and its associated mortality, quality-of-life decrements from ART toxicity, time to ART toxicity, duration of neuropathy and lipodystrophy, and initial CD4 cell count. We also conducted 2-and 3-way sensitivity analyses on key parameters, including the incidence of and mortality from tenofovir-associated nephrotoxicity, initial CD4 cell count, first-line tenofovir efficacy, tenofovir cost, and availability of second-line ART. This had little impact on the cost-effectiveness results (Table 5) .
DISCUSSION
Newer ART agents, including tenofovir, are effective and safer than older NRTIs, but stavudine remains the backbone of firstline ART in India and many resource-limited countries because of its lower cost [6, 28] . We conducted a cost-effectiveness analysis of first-line ART regimens in India, focusing on the role of tenofovir. We found that initial tenofovir increased life expectancy by about 10.3 months, compared with stavudine or zidovudine. At the current price of tenofovir-containing ART ($14/person/month), the incremental cost-effectiveness ratio for initial tenofovir in India was $670/YLS, compared with no ART. The alternative strategies represented a less efficient use of resources. The main determinants of these results were tenofovir cost and both access to and cost of additional lines of ART. Initial stavudine and zidovudine resulted in lower life expectancy than initial tenofovir, likely because tenofovir's better efficacy and toxicity profile resulted in a more durable regimen, fewer switches, and thus, on average, lower mortality. Adjusting for quality of life increased the incremental costeffectiveness ratio of the tenofovir-based strategy to $1000/YLS. Some studies suggest that tenofovir may be associated with nephrotoxicity and renal failure [5] . Several United States-based trials show no increase in nephrotoxicity from tenofovir with careful monitoring and minimal long-term consequences from renal function decline [29] . However, renal toxicity may pose higher risks in resource-limited settings, where experience with tenofovir and laboratory monitoring are more limited and where death from acute renal failure may approach 90% [23, 30] . Sensitivity analyses on nephrotoxicity did not offset the virologic advantages conferred by tenofovir, suggesting that the benefits outweigh potential harm.
In a cost-effectiveness analysis on the use of tenofovir for first-line ART in South Africa, Rosen et al [31] found that tenofovir reduced toxicity and had a high incremental costeffectiveness ratio of about $9000/quality-adjusted life year, compared with stavudine, using monthly costs of $17 for tenofovir and $3.39 for stavudine in US$ at 2007 value. There are several important differences between the Rosen study and the current study, including treatment efficacy, treatment cost, and analysis time frame. We used data that reflected improved effectiveness and smaller differences in cost between initial tenofovir and other first-line alternatives, and we evaluated clinical and cost outcomes over a lifetime rather than 2 years.
We also examined a scenario in which patients had access to only one line of ART, reflecting current limitations in ART rollout capacity, as well as a future scenario with 3 lines of ART. We found that the increased efficacy of first-line tenofovir over the alternatives improved its cost-effectiveness when only one line of ART was available. These results were stable despite changes in the cost of initial tenofovir when 2 lines of ART were available, likely because the cost of initial tenofovir was offset by the alternative, which included a higher-cost, tenofovir-containing second-line regimen. When only one line of ART was available, the cost of initial tenofovir was more important. These findings emphasize the importance of enhancing access to second-line ART in optimizing the use of limited resources for HIV treatment.
Patients with better adherence may be at greater risk for ART toxicities, because drug exposure is necessary to incur adverse events [32] . Toxicities such as lipodystrophy and neuropathy may decrease both the adherence and the durability of firstline ART, although this is not clear [33, 34] . To address these uncertainties, we varied the effectiveness advantage of tenofovir [6, 19] . Although some data have shown that tenofovir and stavudine have similar virologic outcomes, other data suggest that tenofovir confers superior effectiveness over zidovudine after accounting for toxicity [6] . Data on the effectiveness of stavudine-and zidovudine-containing ART from the Therapeutics Research, Education, and AIDS Training in Asia (Treat ASIA) cohort were pooled, resulting in equal effectiveness in the model for either regimen [19] . These data may reflect lower adherence over time for patients on stavudine due to chronic toxicities [35] , and we tested this possibility with extensive sensitivity analyses.
Some studies have suggested that tenofovir combined with nevirapine rather than efavirenz may reduce virologic suppression [36] [37] [38] . If these findings are substantiated, the selection of a nonnucleoside reverse-transcriptase inhibitor for use with tenofovir should take this into account [1] .
Patients who experienced virologic failure on initial tenofovir switched to a second-line regimen containing zidovudine, which is less expensive than the tenofovir-containing secondline regimen. The discounted total lifetime costs of 3 of the ART strategies (initial tenofovir, initial stavudine, and initial stavudine-to-zidovudine) were within a lifetime cost range of $140. Lifetime costs were highest for individuals using zidovudine as part of first-line ART, either initially or following a substitution. This suggests that second-line ART costs are more important contributors to total lifetime costs than first-line ART costs.
This analysis has several limitations. First, published data that compare the effectiveness of alternative ART regimens in resource-limited settings are limited. For stavudine-and zidovudine-based first-line ART, we used data from an observational cohort in India, but for initial tenofovir we used US clinical trials, which may reflect better outcomes. Long-term adherence may be reduced because of toxicity and may explain higher long-term virologic failure for initial zidovudine or stavudine, compared with tenofovir. We examined this possibility and the choice to use pooled data from Treat ASIA for effectiveness of stavudine-and zidovudine-containing ART in extensive sensitivity analyses. When all first-line ART regimens had equal effectiveness, tenofovir resulted in similar life expectancy as initial zidovudine or stavudine. Even in this scenario, tenofovir remained the only efficient first-line ART alternative, because of toxicities associated with the other NRTI options. We did not explicitly model loss to follow-up. However, we used the long-term failure parameter to examine the consequence of reduced adherence on treatment outcomes, which made tenofovir more attractive.
Second, there are limited data about ART toxicities in resource-limited settings. We used published data from India on adverse events related to stavudine and zidovudine but United States-based estimates for nephrotoxicity and other toxicities. Sensitivity analyses (Figure 1 ) suggest that nephrotoxicity is unlikely to alter the finding that tenofovir represents an attractive component of first-line ART in resource-limited settings. Third, this study did not examine outcomes for individuals coinfected with HIV and hepatitis B, so this analysis likely underestimates the benefits of tenofovir-based therapy [39] . Finally, there are scant data on the quality-of-life impact of ART in India [40] . We found that including plausible qualityof-life effects increased the cost-effectiveness ratio of tenofovirbased first-line ART to $1000/YLS, compared with no ART, from the base case ratio of $670/YLS, but this still represents the most efficient use of resources and meets criteria for costeffectiveness.
Determining the best use of limited resources for HIV care is challenging, because the additional short-term expense of initial tenofovir could potentially mean that some HIV-infected patients may not receive needed treatment. Thus, although initial tenofovir may be deemed cost-effective by WHO criteria, it could challenge short-term budget constraints in some countries.
This study has several implications for guidelines on firstline ART in India. Although stavudine and zidovudine are effective, recent substantial price reductions in tenofovir make it a very viable treatment option. As the cost of tenofovir continues to decrease, its use will become even more attractive. Incorporating tenofovir as part of first-line ART in India will improve survival, is cost-effective by international standards, and should be considered for HIV-infected patients in India. 
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